Results of cost-effectiveness analysis
| Cost (€) | QALY | Incremental cost (€) | Incremental efficacy (QALY) | ICER (€/QALY) | |
| Infliximab | 91 604 | 6.28 | 0 | 0 | 0 |
| Adalimumab | 72 671 | 5.85 | −18,933 | −0.43 | 43 928.07 |
| Golimumab | 66 030 | 5.46 | −25,574 | −0.82 | 31 340.69 |
| Vedolizumab | 147 642 | 6.74 | 56 038 | 0.46 | 122 890.35 |
| Tofacitinib | 134 073 | 6.44 | 42 469 | 0.16 | 270 503.19 |
.ICER, Incremental cost-effectiveness ratio; QALY, Quality of life-adjusted years.